Eli Lilly's experimental drug retatrutide achieved strong Phase 3 results for type 2 diabetes. The treatment showed a 2% drop in blood sugar and nearly 17% weight loss over 40 weeks, significantly outperforming the placebo. It also improved cardiovascular health. Despite the positive data, LLY stock remained flat in pre-market trading while attracting high retail interest.